Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Sonia Jain, PhD
Advertisement
Articles by Sonia Jain, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data
2
How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?
3
Will Targeting EVA1 With ADCs Eliminate Glioblastoma-Initiating Cells?
4
Identifying Common Toxicities with Targeted Therapies in GI Malignancies
5
